Drug Trial Radar · NCT06193902
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
17
Planned (sponsor's estimate)
Start
Nov 13, 2023
Primary completion
May 2029
Study completion May 2029
Sponsor
- Lead sponsor
- Leucid BioIndustry
- Sponsor type
- Industry
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.
Conditions
- Tumor, Solid
Interventions
LEU011Biological
Immunotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the dose limiting toxicity, safety and tolerability of a single dose of LEU011 in subjects with NKG2DL expressing relapsed/refractory solid tumoursTime frame: 28 days post administration of LEU011 immunotherapy
- To identify a recommended Phase 2 dose (RP2D) of LEU011Time frame: 28 days post administration of LEU011 immunotherapy
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.